MabVax Therapeutics (NASDAQ:MBVX) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.
Shares of MabVax Therapeutics (NASDAQ:MBVX) traded up $0.06 during trading hours on Friday, hitting $0.77. 499,771 shares of the stock traded hands, compared to its average volume of 548,863. The firm has a market capitalization of $17.70, a P/E ratio of -0.21 and a beta of 1.32. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.80. MabVax Therapeutics has a 52 week low of $0.43 and a 52 week high of $3.57.
MabVax Therapeutics (NASDAQ:MBVX) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.54) earnings per share for the quarter.
A hedge fund recently bought a new stake in MabVax Therapeutics stock. Cambridge Investment Research Advisors Inc. acquired a new position in MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned about 12.33% of MabVax Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 11.53% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “MabVax Therapeutics (MBVX) Lifted to Sell at ValuEngine” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/04/mabvax-therapeutics-mbvx-lifted-to-sell-at-valuengine.html.
About MabVax Therapeutics
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MabVax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.